Literature DB >> 19228602

Venous thromboembolism: risk factors for recurrence.

Tienan Zhu1, Isabelle Martinez, Joseph Emmerich.   

Abstract

Patients who have a first episode of venous thromboembolism (VTE) have an elevated risk of a recurrent episode, and this necessitates secondary prophylaxis. Anticoagulant therapy is a double-edged sword, however, as it reduces the risk of recurrent VTE but increases the risk of hemorrhage. This balance must be taken into account when assessing the risk-benefit ratio of long-term anticoagulation. Some clinical characteristics of the index VTE event can help to categorize the individual risk of recurrence. Patients with persistent risk factors such as cancer have a significantly higher risk of recurrent thrombosis. In contrast, VTE provoked by transient risk factors is associated with a lower risk of recurrence. Intrinsic features of patients with VTE (gender, age, hereditary thrombophilia) have also been linked to the risk of recurrent VTE. There is increasing evidence that a normal D-dimer level and the absence of residual venous thrombosis after discontinuation of oral anticoagulation are associated with a lower risk of recurrent VTE events. Future studies are needed to refine the predictive value of known risk factors for VTE recurrence and to discover better markers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228602     DOI: 10.1161/ATVBAHA.108.182428

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  45 in total

1.  [Treatment of deep vein thrombosis and pulmonary embolism].

Authors:  S M Schellong
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

Review 2.  Predicting the risk of venous thromboembolism recurrence.

Authors:  John A Heit
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

3.  Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study.

Authors:  Yunfeng Zhang; Qixing Zhou; Ying Zou; Xiaolian Song; Shuanshuan Xie; Min Tan; Guoliang Zhang; Changhui Wang
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

Review 4.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

5.  Myeloid cell tissue factor does not contribute to venous thrombogenesis in an electrolytic injury model.

Authors:  Anna L Hampton; Jose A Diaz; Angela E Hawley; Shirley K Wrobleski; Jian-Guo Wang; Rebecca D Lee; Daniel Kirchhofer; Robert E Sigler; Thomas W Wakefield; Nigel Mackman; Daniel D Myers
Journal:  Thromb Res       Date:  2011-12-20       Impact factor: 3.944

6.  Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective.

Authors:  Amisha M Parikh; Frederick A Spencer; Darleen Lessard; Catherine Emery; Ana Baylin; Crystal Linkletter; Robert J Goldberg
Journal:  Am J Kidney Dis       Date:  2011-08-27       Impact factor: 8.860

7.  Discontinuation of anticoagulant care during admission to a psychiatric hospital.

Authors:  H Abdullah-Koolmees; T Gerbranda; V H M Deneer; M M Tjoeng; A J M De Ridder; H Gardarsdottir; E R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

8.  Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.

Authors:  Abrar Ahmad; Kristina Sundquist; Bengt Zöller; Peter J Svensson; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 9.  Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.

Authors:  Kang-Ling Wang; Pao-Hsien Chu; Cheng-Han Lee; Pei-Ying Pai; Pao-Yen Lin; Kou-Gi Shyu; Wei-Tien Chang; Kuan-Ming Chiu; Chien-Lung Huang; Chung-Yi Lee; Yen-Hung Lin; Chun-Chieh Wang; Hsueh-Wei Yen; Wei-Hsian Yin; Hung-I Yeh; Chern-En Chiang; Shing-Jong Lin; San-Jou Yeh
Journal:  Acta Cardiol Sin       Date:  2016-01       Impact factor: 2.672

10.  Venous thromboembolism: risk factors, biomarkers, and treatment.

Authors:  Alisa S Wolberg; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.